Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Detection of mutations in arylsulfatase A gene in cerebral palsy - two different approaches (CROSBI ID 542072)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Mlinac, Kristina ; Kalanj Bognar, Svjetlana ; Furač, Ivana ; Grubešić, Zdravko Detection of mutations in arylsulfatase A gene in cerebral palsy - two different approaches // Abstract book of the 3rd ESF Functional Genomics Conference. Innsbruck, 2008. str. 107-108

Podaci o odgovornosti

Mlinac, Kristina ; Kalanj Bognar, Svjetlana ; Furač, Ivana ; Grubešić, Zdravko

engleski

Detection of mutations in arylsulfatase A gene in cerebral palsy - two different approaches

Lower activity of lysosomal enzyme arylsulfatase A (ASA, EC 3.1.6.8) was observed in leukocytes of patients with cerebral palsy, a neurodevelopmental disorder of complex ethiopathogenesis. The aim of this study was to estimate possible contribution of four described mutations in ASA gene: two most common mutations associated with ASA-pseudodeficiency (N350S and 1524+95 A-G) and two most common mutations underlying metachromatic leukodystrophy, MLD (P426L and 459+1 G-A). Mutations associated with metachromatic leukodystrophy were detected using two different methods previously described, but unexpectedly different results were obtained. According to the first method, P426L and 459+1 G-A mutations were detected by digestion with Xba I and Pst I, respectively. Using this method, the 459+1 G-A mutation was detected in 9 of 56 individuals, while P426L mutation was found to be present in even 12 of 64 individuals. Estimated frequencies of determined mutations were thus surprisingly high in the analyzed group of patients (8 % and 9.37 %, respectively). In order to check the results, we used another genotyping method, which detects the polymorphisms with different restriction enzymes, Aci I (for the P426L mutation) and Bst NI (for the 459+1 G-A mutation). In analyzed group of patients no mutation was found and thus no confirmation of previous results was obtained. In order to clarify which of the methods would give more reliable results, we sequenced fragments of ASA gene amplified with two different pair of primers, according to two different methods described for estimation of MLD mutations. Samples with and without mutation were sequenced and obtained results were compared for two different genotyping approaches. In conclusion, ASA activity found to be lower in patients with cerebral palsy may be related to detected mutations associated with ASA pseudodeficiency and MLD, and most probably with yet undescribed mutated sites in the ASA gene.

arylsulfatase A; cerebral palsy

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

107-108.

2008.

objavljeno

Podaci o matičnoj publikaciji

Abstract book of the 3rd ESF Functional Genomics Conference

Innsbruck:

Podaci o skupu

3rd ESF Functional Genomics Conference: Functional Genomics and Disease

poster

01.10.2008-04.10.2008

Innsbruck, Austrija

Povezanost rada

Temeljne medicinske znanosti